A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk

Show simple item record

dc.contributor.author Lu, Yingchang
dc.contributor.author Beeghly-Fadiel, Alicia
dc.contributor.author Wu, Lang
dc.contributor.author Guo, Xingyi
dc.contributor.author Li, Bingshan
dc.contributor.author Schildkraut, Joellen M.
dc.contributor.author Im, HaeKyung
dc.contributor.author Chen, Yian A.
dc.contributor.author Permuth, Jennifer B.
dc.contributor.author Reid, Brett M.
dc.contributor.author Teer, Jamie K.
dc.contributor.author Moysich, Kirsten B.
dc.contributor.author Andrulis, Irene L.
dc.contributor.author Anton-Culver, Hoda
dc.contributor.author Arun, Banu K.
dc.contributor.author Bandera, Elisa V.
dc.contributor.author Barkardottir, Rosa B.
dc.contributor.author Barnes, Daniel R.
dc.contributor.author Benitez, Javier
dc.contributor.author Bjorge, Line
dc.contributor.author Brenton, James
dc.contributor.author Butzow, Ralf
dc.contributor.author Caldes, Trinidad
dc.contributor.author Caligo, Maria A.
dc.contributor.author Campbell, Ian
dc.contributor.author Chang-Claude, Jenny
dc.contributor.author Claes, Kathleen B.M.
dc.contributor.author Couch, Fergus J.
dc.contributor.author Cramer, Daniel W.
dc.contributor.author Daly, Mary B.
dc.contributor.author DeFazio, Anna
dc.contributor.author Dennis, Joe
dc.contributor.author Diez, Orland
dc.contributor.author Domchek, Susan M.
dc.contributor.author Dörk, Thilo
dc.contributor.author Easton, Douglas F.
dc.contributor.author Eccles, Diana M.
dc.contributor.author Fasching, Peter A.
dc.contributor.author Fortner, Renée T.
dc.contributor.author Fountzilas, George
dc.contributor.author Friedman, Eitan
dc.contributor.author Ganz, Patricia A.
dc.contributor.author Garber Judy
dc.contributor.author Giles, Graham G.
dc.contributor.author Godwin, Andrew K.
dc.contributor.author Goldgar, David E.
dc.contributor.author Goodman, Marc T.
dc.contributor.author Greene, Mark H.
dc.contributor.author Gronwald, Jacek
dc.contributor.author Hamann, Ute
dc.contributor.author Heitz, Florian
dc.contributor.author Hildebrandt, Michelle A.T.
dc.contributor.author Høgdall, Claus K.
dc.contributor.author Hollestelle, Antoinette
dc.contributor.author Hulick, Peter J.
dc.contributor.author Huntsman, David G.
dc.contributor.author Imyanitov, Evgeny N.
dc.contributor.author Isaacs, Claudine
dc.contributor.author Jakubowska, Anna
dc.contributor.author James, Paul
dc.contributor.author Karlan, Beth Y.
dc.contributor.author Kelemen, Linda E.
dc.contributor.author Kiemeney, Lambertus A.
dc.contributor.author Kjaer, Susanne K.
dc.contributor.author Kwong, Ava
dc.contributor.author Le, Nhu D.
dc.contributor.author Leslie, Goska
dc.contributor.author Lesueur, Fabienne
dc.contributor.author Levine, Douglas A.
dc.contributor.author Mattiello, Amalia
dc.contributor.author May, Taymaa
dc.contributor.author McGuffog, Lesley
dc.contributor.author McNeish, Iain A.
dc.contributor.author Merritt, Melissa A.
dc.contributor.author Modugno, Francesmary
dc.contributor.author Montagna, Marco
dc.contributor.author Neuhausen, Susan L.
dc.contributor.author Nevanlinna, Heli
dc.contributor.author Nielsen, Finn C.
dc.contributor.author Nikitina-Zake, Liene
dc.contributor.author Nussbaum, Robert L.
dc.contributor.author Offit, Kenneth
dc.contributor.author Olah, Edith
dc.contributor.author Olopade, Olufunmilayo I.
dc.contributor.author Olson, Sara H.
dc.contributor.author Olsson, Håkan K.
dc.contributor.author Osorio, Ana
dc.contributor.author Park, Sue K.
dc.contributor.author Parsons, Michael T.
dc.contributor.author Peeters, Petra H.M.
dc.contributor.author Pejovic, Tanja
dc.contributor.author Peterlongo, Paolo
dc.contributor.author Phelan, Catherine M.
dc.contributor.author Pujana, Miquel Angel
dc.contributor.author Ramus, Susan J.
dc.contributor.author Rennert, Gad
dc.contributor.author Risch, Harvey
dc.contributor.author Rodriguez, Gustavo C.
dc.contributor.author Rodríguez-Antona, Cristina
dc.contributor.author Romieu, Isabelle
dc.contributor.author Rookus, Matti A.
dc.contributor.author Rossing, Mary Anne
dc.contributor.author Rzepecka, Iwona K.
dc.contributor.author Sandler, Dale P.
dc.contributor.author Schmutzler, Rita K.
dc.contributor.author Setiawan, Veronica W.
dc.contributor.author Sharma, Priyanka
dc.contributor.author Sieh, Weiva
dc.contributor.author Simard, Jacques
dc.contributor.author Singer, Christian F.
dc.contributor.author Song, Honglin
dc.contributor.author Southey, Melissa C.
dc.contributor.author Spurdle, Amanada B.
dc.contributor.author Sutphen, Rebecca
dc.contributor.author Swerdlow, Anthony J.
dc.contributor.author Teixeira, Manuel R.
dc.contributor.author Teo, Soo H.
dc.contributor.author Thomassen, Mads
dc.contributor.author Tischkowitz, Marc
dc.contributor.author Toland, Amanda E.
dc.contributor.author Trichopoulou, Antonia
dc.contributor.author Tung, Nadine
dc.contributor.author Tworoger, Shelley S.
dc.contributor.author Jansen van Rensburg, Elizabeth
dc.contributor.author Vanderstichele, Adriaan
dc.contributor.author Vega, Ana
dc.contributor.author Edwards, Digna Velez
dc.contributor.author Webb, Penelope M.
dc.contributor.author Weitzel, Jeffrey N.
dc.contributor.author Wentzensen, Nicolas
dc.contributor.author White, Emily
dc.contributor.author Wolk, Alicja
dc.contributor.author Wu, Anna H.
dc.contributor.author Yannoukakos, Drakoulis
dc.contributor.author Zorn, Kristin K.
dc.contributor.author Gayther, Simon A.
dc.contributor.author Antoniou, Antonis C.
dc.contributor.author Berchuck, Andrew
dc.contributor.author Goode, Ellen L.
dc.contributor.author Chenevix-Trench, Georgia
dc.contributor.author Sellers, Thomas A.
dc.contributor.author Pharoah, Paul D.P.
dc.contributor.author Zheng, Wei
dc.contributor.author Long, Jirong
dc.date.accessioned 2019-04-09T08:01:16Z
dc.date.issued 2018-09
dc.description Online Supplementary Materials - Online Supplementary Documents en_ZA
dc.description Table S1 - Internal performance of ovarian and cross-tissue gene expression prediction models built using GTEx data. en_ZA
dc.description Table S2 - Chromosomal regions with predicted gene expression levels associated with epithelial ovarian cancer risk at P < 2.21E-6 with either ovarian or cross-tissue model. en_ZA
dc.description Table S3 - Known common variants identified from genome-wide assocation studies and their bioinformatically predicted target genes. en_ZA
dc.description Table S4 - Association results after the adjustment for nearby GWAS index SNPs for genes with predicted gene expression levels associated with ovarian cancer risk at P < 2.21E-6. en_ZA
dc.description Table S5 - Genes coregulated in predicted expression at 2q31.1, 9p22.3, 17q21.31 and 17q21.32. en_ZA
dc.description Table S6 - Association results between associated genes with P < P < 2.21E-6 and risk of different histotypes of epithelial ovarian cancer. en_ZA
dc.description Table S7 - Variants with P < 5E-8 either in BCAC or OCAC between 42,836,399 and 44,910,520 on the chromosome 17. en_ZA
dc.description Table S8 - Association results between minor alleles of 467 variants incorportated in cross tissue gene expression prediction model for the gene of CRHR1. en_ZA
dc.description.abstract Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease susceptibility variants are located in noncoding regions, and causal genes underlying these associations remain largely unknown. Here, we performed a transcriptome-wide association study to search for novel genetic loci and plausible causal genes at known GWAS loci. We used RNA sequencing data (68 normal ovarian tissue samples from 68 individuals and 6,124 cross-tissue samples from 369 individuals) and high-density genotyping data from European descendants of the Genotype-Tissue Expression (GTEx V6) project to build ovarian and cross-tissue models of genetically regulated expression using elastic net methods. We evaluated 17,121 genes for their cis-predicted gene expression in relation to EOC risk using summary statistics data from GWAS of 97,898 women, including 29,396 EOC cases. With a Bonferroni-corrected significance level of P < 2.2 × 10−6, we identified 35 genes, including FZD4 at 11q14.2 (Z = 5.08, P = 3.83 × 10−7, the cross-tissue model; 1 Mb away from any GWAS-identified EOC risk variant), a potential novel locus for EOC risk. All other 34 significantly associated genes were located within 1 Mb of known GWAS-identified loci, including 23 genes at 6 loci not previously linked to EOC risk. Upon conditioning on nearby known EOC GWAS-identified variants, the associations for 31 genes disappeared and three genes remained (P < 1.47 × 10−3). These data identify one novel locus (FZD4) and 34 genes at 13 known EOC risk loci associated with EOC risk, providing new insights into EOC carcinogenesis. Significance : Transcriptomic analysis of a large cohort confirms earlier GWAS loci and reveals FZD4 as a novel locus associated with EOC risk. en_ZA
dc.description.department Genetics en_ZA
dc.description.embargo 2019-09-01
dc.description.librarian hj2019 en_ZA
dc.description.sponsorship The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113. The results published here are in part based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7). The OCAC OncoArray genotyping project was funded through grants from the NIH [U19-CA148112 (to T.A. Sellers), R01-CA149429 (to C.M. Phelan), and R01-CA058598 (to M.T. Goodman); Canadian Institutes of Health Research (MOP-86727 (to L.E. Kelemen)] and the Ovarian Cancer Research Fund (to A. Berchuck). The COGS project was funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175). Funding for individual studies: AAS: NIH (RO1-CA142081); AOV: The Canadian Institutes for Health Research (MOP-86727); AUS: The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211, and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; BAV: ELAN Funds of the University of Erlangen-Nuremberg; BEL: National Kankerplan; BGS: Breast Cancer Now, Institute of Cancer Research; BVU: Vanderbilt CTSA grant from the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) (ULTR000445); CAM: National Institutes of Health Research Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Cancer Centre; CHA: Innovative Research Team in University (PCSIRT) in China (IRT1076); CNI: Instituto de Salud Carlos III (PI 12/01319); Ministerio de Economía y Competitividad (SAF2012); COE: Department of Defense (W81XWH-11-2-0131); CON: National Institutes of Health (R01-CA063678, R01-CA074850; R01-CA080742); DKE: Ovarian Cancer Research Fund and National Institutes of Health 1R01CA211574 (J.M. Schildkraut); DOV: National Institutes of Health R01-CA112523 and R01-CA87538; EMC: Dutch Cancer Society (EMC 2014-6699); EPC: The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom); GER: German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ); GRC: This research has been co-financed by the European Union (European Social Fund - ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in knowledge society through the European Social Fund; GRR: Roswell Park Cancer Institute Alliance Foundation, P30 CA016056; HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HJO: Intramural funding; Rudolf-Bartling Foundation; HMO: Intramural funding; Rudolf-Bartling Foundation; HOC: Helsinki University Research Fund; HOP: Department of Defense (DAMD17-02-1-0669) and NCI (K07-CA080668, R01-CA95023, P50-CA159981 MO1-RR000056 R01-CA126841); HUO: Intramural funding; Rudolf-Bartling Foundation; JGO: JSPS KAKENHI grant; JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare; KRA: This study (Ko-EVE) was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (HI16C1127; 0920010); LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124; LUN: ERC-2011-AdG 294576-risk factors cancer, Swedish Cancer Society, Swedish Research Council, Beta Kamprad Foundation; MAC: NIH (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles; MAL: Funding for this study was provided by research grant R01- CA61107 from the National Cancer Institute, Bethesda, MD, research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project; MAS: Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation; MAY: National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MCC: Cancer Council Victoria, National Health and Medical Research Council of Australia (NHMRC) grants number 209057, 251533, 396414, and 504715; MDA: DOD Ovarian Cancer Research Program (W81XWH-07-0449); MEC: NIH (CA54281, CA164973, CA63464); MOF: Moffitt Cancer Center, Merck Pharmaceuticals, the state of Florida, Hillsborough County, and the city of Tampa; NCO: National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NHS: UM1 CA186107, P01 CA87969, R01 CA49449, R01-CA67262, UM1 CA176726; NJO: National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, P30-CA072720, and P30-CA008748) and the Cancer Institute of New Jersey; NOR: Helse Vest, The Norwegian Cancer Society, The Research Council of Norway; NTH: Radboud University Medical Centre; OPL: National Health and Medical Research Council (NHMRC) of Australia (APP1025142) and Brisbane Women's Club; ORE: OHSU Foundation; OVA: This work was supported by Canadian Institutes of Health Research grant (MOP-86727) and by NIH/NCI 1 R01CA160669-01A1; PLC: Intramural Research Program of the National Cancer Institute; POC: Pomeranian Medical University; POL: Intramural Research Program of the National Cancer Institute; PVD: Canadian Cancer Society and Cancer Research Society GRePEC Program; RBH: National Health and Medical Research Council of Australia; RMH: Cancer Research UK, Royal Marsden Hospital; RPC: National Institute of Health (P50 CA159981, R01CA126841); SEA: Cancer Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; SIS: NIH, National Institute of Environmental Health Sciences, Z01 ES044005 and Z01-ES049033; SMC: The Swedish Research Council; SON: National Health Research and Development Program, Health Canada, grant 6613-1415-53; SRO: Cancer Research UK (C536/A13086, C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589); STA: NIH grants U01 CA71966 and U01 CA69417; SWE: Swedish Cancer foundation, WeCanCureCancer and årKampMotCancer foundation; SWH: NIH (NCI) grant R37-CA070867; TBO: National Institutes of Health (R01-CA106414-A2), American Cancer Society (CRTG-00-196-01-CCE), Department of Defense (DAMD17-98-1-8659), Celma Mastery Ovarian Cancer Foundation; TOR: NIH grants R01 CA063678 and R01 CA063682; UCI: NIH R01-CA058860 and the Lon V Smith Foundation grant LVS-39420; UHN: Princess Margaret Cancer Centre Foundation-Bridge for the Cure; UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre; UKR: Cancer Research UK (C490/A6187), UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; USC: P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200); VAN: BC Cancer Foundation, VGH & UBC Hospital Foundation; VTL: NIH K05-CA154337; WMH: National Health and Medical Research Council of Australia, Enabling Grants ID 310670 & ID 628903. Cancer Institute NSW Grants 12/RIG/1-17 & 15/RIG/1-16; WOC: National Science Centren (N N301 5645 40). The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of the Ovarian Cancer Association Consortium through their donations to the Ovarian Cancer Research Fund. The OncoArray and COGS genotyping projects would not have been possible without the contributions of the following: Per Hall (COGS); Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), Marjorie J. Riggan (OCAC), Rosalind A. Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Jonathan P. Tyrer, Siddhartha Kar, Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility. We pay special tribute to the contribution of Professor Brian Henderson to the GAME-ON consortium and to Olga M. Sinilnikova for her contribution to CIMBA and for her part in the initiation and coordination of GEMO until she sadly passed away on the 30th June 2014. We thank the study participants, doctors, nurses, clinical and scientific collaborators, health care providers and health information sources who have contributed to the many studies contributing to this manuscript. en_ZA
dc.description.uri http://cancerres.aacrjournals.org en_ZA
dc.identifier.citation Lu, Y., Beeghly-Fadiel, A., Wu, L. et al. 2018, 'A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk', Cancer Research, vol. 78, no. 18, pp. 5419-5430. en_ZA
dc.identifier.issn 0008-5472 (print)
dc.identifier.issn 1538-7445 (online)
dc.identifier.other 10.1158/0008-5472.CAN-18-0951
dc.identifier.uri http://hdl.handle.net/2263/68936
dc.language.iso en en_ZA
dc.publisher American Association for Cancer Research en_ZA
dc.rights © 2018 American Association for Cancer Research en_ZA
dc.subject Genome-wide association studies (GWAS) en_ZA
dc.subject Epithelial ovarian cancer (EOC) en_ZA
dc.subject Corticotropin-releasing hormone en_ZA
dc.subject Multiple en_ZA
dc.subject HOXB2 en_ZA
dc.subject Identification en_ZA
dc.subject Variants en_ZA
dc.subject Expression en_ZA
dc.subject Loci en_ZA
dc.subject Breast cancer en_ZA
dc.subject In vitro fertilization (IVF) en_ZA
dc.title A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record